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Introduction {#j_raon-2018-0005_s_001}
============

Malignant mesothelioma (MM) is a rare disease, linked to asbestos exposure in more than 80% of the cases. The latency period can last up to thirty years and estimated median survival is 9--12 months. The worldwide incidence of mesothelioma is slowly rising, with approximately 94 000 new cases per year. The most affected areas are parts of Europe, Australia and the USA.[@j_raon-2018-0005_ref_001] The rise in the MM incidence has been noticed in the Slovene population as well. The Slovenian national registry follows the data on MM since 1961. The incidence in 2014 was 37 new cases per year in a population of approximately 2 million.[@j_raon-2018-0005_ref_002]

Several preclinical studies have identified matrix metalloproteinases (MMPs) as modulators of the tumour microenvironment and having an important role in carcinogenesis.[@j_raon-2018-0005_ref_003] MMPs are calcium-dependent, zinc-containing endopeptidases, with three common domains containing the propeptide, catalytic and haemopexin-like C-terminal domain.[@j_raon-2018-0005_ref_004] They are involved in tissue remodelling by interfering with the cell-cell and cell-extracellular matrix interactions. Studies have shown that MMPs, particularly MMP-2 and MMP-9, play a role in tumour angiogenesis, invasion and metastasis.[@j_raon-2018-0005_ref_005] The studies performed thus far show that MMPs and their inhibitory molecules, tissue inhibitors of metalloproteinases (TIMPs), have an important role in proliferation and progression of MM and some other, more frequent malignancies, such as colon and breast cancer. Different MMP genes (*MMP2*, *MMP9*, *MMP11*, *MMP14*) and their expression were studied in mesothelioma tissue as potential prognostic markers.[@j_raon-2018-0005_ref_006] In a previous paper we studied the possible role of single nucleotide polymorphisms (SNPs) as potential markers of treatment response.[@j_raon-2018-0005_ref_007] We identified *MMP9* rs2250889, *MMP9 rs20544*, *MMP14* rs1042703 as statistically significantly associated with overall survival (OS) in MM. Carriers of the polymorphic *MMP9* rs2250889 and *MMP14* rs1042703 alleles had shorter OS, compared to non-carriers, while carriers of polymorphic *MMP9* rs20544 allele had longer OS.[@j_raon-2018-0005_ref_007]

Many studies investigated the role of *MMP* polymorphisms in the baseline genetic risk for common diseases and tumours, however, the role of *MMP* polymorphisms was found to be conflicting in different diseases. In a large nested case-control study investigating skin cancer risk, *MMP9* Arg668Gln polymorphism has been associated with a decreased risk of squamous cell skin cancer (SCC).[@j_raon-2018-0005_ref_008]

The opposite effect was observed in T-cell acute lymphoblastic leukaemia (T-ALL), where *MMP2* rs243865 and *MMP9* rs3918242 polymorphisms were associated with an increased risk of T-ALL.[@j_raon-2018-0005_ref_009]

The data from the literature, linking *MMP* polymorphisms with tumour risk and the statistically significant associations between the selected *MMP2*, *MMP9* and *MMP14* SNPs and time to progression (TTP) and OS in MM, led us to further investigate their potential role in baseline genetic risk of MM development. Our aim was to investigate selected *MMP* polymorphisms as baseline risk predictors in MM development in combination with other well known risk factors, such as asbestos exposure.

Patients and methods {#j_raon-2018-0005_s_002}
====================

Patients {#j_raon-2018-0005_s_002_s_001}
--------

Patients with histologically confirmed pleural or peritoneal mesothelioma diagnosed and treated between 2007 and 2016 were included in this retrospective study. Patients were diagnosed mostly at the University Clinic Golnik and at the Department of Thoracic Surgery of the University Medical Centre Ljubljana. Patients were treated and followed-up at the Institute of Oncology Ljubljana, Slovenia.

Most patients included in the study were also participating in previous studies on pharmacogenomics of MM treatment, conducted at the Institute of Oncology Ljubljana, Slovenia. Some of the patients were also included in the clinical trial AGILI (Trial registration ID: NCT01281800).[@j_raon-2018-0005_ref_010]

Clinical characteristics at diagnosis were obtained from medical records or assessed during clinical interview. Regarding asbestos exposure, patients were divided in two groups: patients with no known asbestos exposure and patients with known occupational or environmental exposure.

The control group consisted of 161 unrelated healthy Slovenian blood donors, aged 49 to 65.

The study was approved by the Slovenian National Medical Ethics Committee and was carried out according to the Declaration of Helsinki.

DNA extraction and genotyping {#j_raon-2018-0005_s_002_s_002}
-----------------------------

Genomic DNA was extracted from frozen whole-blood samples collected at the inclusion in any of the above mentioned studies using the Qiagen FlexiGene Kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions.

Ten different polymorphisms in three *MMP* genes were genotyped: *MMP2* rs243865, rs243849 and rs7201, *MMP9* rs17576, rs17577, rs2250889 and rs20544, and *MMP14* rs1042703, rs1042704 and rs743257. Predicted function of these polymorphisms was assessed using SNP Function Prediction tools.[@j_raon-2018-0005_ref_011]

The genotyping of all the SNPs was carried out using a fluorescence-based competitive allele-specific assay (KASPar), according to the manufacturer's instructions (LGC Genomics, UK).

For all investigated polymorphisms, 15% of samples were genotyped in duplicates. Genotyping quality control criteria included 100% duplicate call rate and 90% SNP-wise call rate.

Statistical analyses {#j_raon-2018-0005_s_002_s_003}
--------------------

Continuous and categorical variables were described using median and range (25%-75%) and frequencies, respectively. Deviation from the Hardy-Weinberg equilibrium (HWE) was assessed using the standard chi-square test. The additive and dominant genetic models were used in statistical analyses. The associations of genetic polymorphisms with MM risk were examined by logistic regression to calculate odds ratios (ORs) and their 95% confidence intervals (CIs).

All statistical analyses were carried out by IBM SPSS Statistics, version 21.0 (IBM Corporation, Armonk, NY, USA). Haplotypes were reconstructed and analysed using Thesias software, version 3.1. The most frequent haplotype was used as the reference. All statistical tests were two sided and the level of significance was set to P = 0.05. Due to the exploratory nature of the study, no adjustments for multiple comparisons were used.

Results {#j_raon-2018-0005_s_003}
=======

Patient characteristics {#j_raon-2018-0005_s_003_s_001}
-----------------------

In total, we included 236 patients with MM and 161 healthy blood donors as a control group. Clinical characteristics of patients are summarized in [Table 1](#j_raon-2018-0005_tab_001){ref-type="table"}. Among controls, 125 (77.6%) were male and 36 (22.4%) were female. Median age was 55 (52--58.5) years. There were no significant differences between cases and controls regarding gender (P = 0.375), however, controls were significantly younger than MM patients (P \< 0.001).

###### 

Patients' characteristics (N = 236)

  Characteristic                                  N (%)
  ---------------------------- ------------------ -----------------
  **Gender**                   Male               174 (73.7)
  Female                       62 (26.3)          
  **Age**                      Median (25%-75%)   66 (58-72)
  **Stage**                    I                  18 (7.6)
  II                           60 (25.4)          
  III                          70 (29.7)          
  IV                           67 (28.4)          
  Peritoneal                   20 (8.5)           
  Not determined               1 (0.4)            
  **Histological type**        Epitheloid         169 (71.6)
  Biphasic                     27 (11.4)          
  Sarcomatoid                  26 (11.0)          
  Not characterized            14 (5.9)           
  **ECOG performance stats**   0                  15 (6.4)
  1                            114 (48.3)         
  2                            92 (39.0)          
  3                            15 (6.4)           
  **Metastases**               No                 206 (87.3)
  Yes                          30 (12.7)          
  **Asbestos exposure**        Not exposed        61 (26.5) \[6\]
  Exposed                      169 (73.5)         
  **Smoking**                  No                 123 (57.7)
  Yes                          106 (46.3)         

Numbers in square brackets denote the number of patients with missing data.

ECOG = Eastern Cooperative Oncology Group

Genotyping analysis {#j_raon-2018-0005_s_003_s_002}
-------------------

Variant allele frequencies for investigated SNPs are presented in [Table 2](#j_raon-2018-0005_tab_002){ref-type="table"}. The distributions of all the investigated SNPs in the control group were in agreement with the Hardy-Weinberg equilibrium.

###### 

Variant allele characteristics, frequencies and agreement with HWE

  Gene        SNP                       SNP characteristics    Variant allele frequency   P~HWE~
  ----------- ------------------------- ---------------------- -------------------------- --------
  *MMP2*      rs243865                  c.-1306C\>T            0.24                       0.165
  rs243849    c.999C\>T, p.Asp333=      0.14                   0.798                      
  rs7201      c.^∗^260A\>C              0.41                   0.441                      
  *MMP9*      rs17576                   c.836AG, p.Gln279Arg   0.36                       0.785
  rs2250889   c.836A\>G, p.Gln279Arg    0.05                   0.535                      
  rs17577     c.2003G\>A, p.Arg668Gln   0.15                   0.096                      
  rs20544     c.^∗^C\>T                 0.44                   0.445                      
  *MMP14*     rs1042703                 c.22T\>C, p.Pro8Ser    0.26                       0.164
  rs1042704   c.817G\>A, p.Asp273Asn    0.20                   0.830                      
  rs743257    c.^∗^3C\>T                0.50                   0.519                      

HWE = Hardy-Weinberg equilibrium; SNP = single nucleotide polymorphism

Duplicate call rate was 100% for all SNPs. With the exception of one SNP that had a call rate of 92%, all SNPs had a call rate above 97%.

Genotype frequencies for cases and controls are presented in [Table 3](#j_raon-2018-0005_tab_003){ref-type="table"}. Carriers of at least one polymorphic *MMP2* rs243865 allele tended to have a decreased risk for MM (OR = 0.66, 95% CI = 0.44-1.00; P = 0.050). The association was more pronounced in patients with known asbestos exposure: carriers of at least one polymorphic allele had significantly lower MM risk (OR = 0.55, 95% CI = 0.35--0.86; P = 0.009). As the number of homozygotes for polymorphic allele was low, we only observed a significant association with decreased MM risk for heterozygotes in the additive model ([Table 3](#j_raon-2018-0005_tab_003){ref-type="table"}).

###### 

The association of investigated SNPs with risk for malignant mesothelioma

  SNP                 Genotype     Controls N (%)      Cases N (%)         OR (95% CI)   P            Cases exposed to asbestos N (%)   OR (95% CI)   P
  ------------------- ------------ ------------------- ------------------- ------------- ------------ --------------------------------- ------------- ---
  *MMP2* rs243865     CC           90 (55.9)           155 (65.7)          Ref.                       118 (69.8)                        Ref.          
  CT                  65 (40.4)    77 (32.6)           0.69 (0.45-1.05)    0.081         48 (28.4)    0.56 (0.35-0.89)                  **0.015**     
  TT                  6 (3.7)      4 (1.7)             0.39 (0.11-1.41)    0.150         3 (1.8)      0.38 (0.09-1.57)                  0.181         
  CT+TT               71 (44.1)    81 (34.3)           0.66 (0.44-1.00)    **0.050**     51 (30.2)    0.55 (0.35-0.86)                  **0.009**     
  *MMP2* rs243849     CC           108 (75.0) \[17\]   163 (71.5) \[8\]    Ref.                       116 (71.2) \[6\]                  Ref.          
  CT                  33 (22.9)    57 (25.0)           1.14 (0.70-1.87)    0.592         42 (25.8)    1.18 (0.70-2.00)                  0.527         
  TT                  3 (2.1)      8 (3.5)             1.77 (0.46-6.81)    0.408         5 (3.1)      1.55 (0.36-6.65)                  0.554         
  CT+TT               36 (25.0)    65 (28.5)           1.20 (0.74-1.92)    0.459         47 (28.8)    1.22 (0.73-2.02)                  0.451         
  *MMP2* rs7201       AA           56 (35.9) \[5\]     78 (33.5) \[3\]     Ref.                       63 (37.5) \[1\]                   Ref.          
  AC                  71 (45.5)    114 (48.9)          1.15 (0.73-1.81)    0.539         78 (46.4)    0.98 (0.60-1.58)                  0.923         
  CC                  29 (18.6)    41 (17.6)           1.02 (0.56-1.82)    0.960         27 (16.1)    0.83 (0.44-1.56)                  0.560         
  AC+CC               100 (64.1)   155 (66.5)          1.11 (0.73-1.70)    0.622         105 (62.5)   0.93 (0.59-1.47)                  0.765         
  *MMP9* rs17576      AA           64 (40.3) \[2\]     100 (42.9) \[3\]    Ref.                       74 (44.3) \[2\]                   Ref.          
  AG                  75 (47.2)    114 (48.9)          0.97 (0.63-1.49)    0.900         79 (47.3)    0.91 (0.57-1.44)                  0.691         
  GG                  20 (12.6)    19 (8.2)            0.61 (0.30-1.23)    0.165         14 (8.4)     0.61 (0.28-1.30)                  0.196         
  AG+GG               95 (59.8)    133 (57.1)          0.90 (0.59-1.35)    0.599         93 (55.7)    0.85 (0.55-1.31)                  0.458         
  *MMP9* rs2250889    GG           146 (90.7)          212 (90.2) \[1\]    Ref.                       152 (89.9)                        Ref.          
  GA                  15 (9.3)     23 (9.8)            1.06 (0.53-2.09)    0.876         17 (10.1)    1.09 (0.52-2.26)                  0.820         
  *MMP9* rs17577      GG           113 (70.2)          169 (72.8) \[4\]    Ref.                       119 (71.3) \[2\]                  Ref.          
  GA                  47 (29.2)    60 (25.9)           0.85 (0.54-1.34)    0.490         45 (26.9)    0.91 (0.56-1.47)                  0.699         
  AA                  1 (0.6)      3 (1.3)             2.01 (0.21-19.53)   0.549         3 (1.8)      2.85 (0.29-27.79)                 0.368         
  GA+AA               48 (29.8)    63 (27.2)           0.88 (0.56-1.37)    0.565         48 (28.7)    0.95 (0.59-1.53)                  0.831         
  *MMP9* rs20544      CC           33 (20.6) \[1\]     38 (16.3) \[3\]     Ref.                       29 (17.4) \[2\]                   Ref.          
  CT                  74 (46.3)    121 (51.9)          1.42 (0.82-2.46)    0.210         82 (49.1)    1.26 (0.70-2.27)                  0.441         
  TT                  53 (33.1)    74 (31.8)           1.21 (0.68-2.18)    0.518         56 (33.5)    1.20 (0.64-2.25)                  0.563         
  CT+TT               127 (79.4)   195 (83.7)          1.33 (0.79-2.24)    0.275         138 (82.6)   1.24 (0.71-2.15)                  0.453         
  *MMP14* rs1042703   TT           90 (57.0) \[3\]     147 (63.4) \[4\]    Ref.                       109 (65.7) \[3\]                  Ref.          
  TC                  54 (34.2)    67 (28.9)           0.76 (0.49-1.18)    0.225         44 (26.5)    0.67 (0.41-1.09)                  0.110         
  CC                  14 (8.9)     18 (7.8)            0.79 (0.37-1.66)    0.530         13 (7.8)     0.77 (0.34-1.71)                  0.518         
  TC+CC               68 (43.0)    85 (36.6)           0.77 (0.51-1.16)    0.204         57 (34.3)    0.69 (0.44-1.08)                  0.108         
  *MMP14* rs1042704   GG           103 (64.0)          160 (68.1) \[1\]    Ref.                       113 (66.9)                        Ref.          
  GA                  51 (31.7)    64 (27.2)           0.81 (0.52-1.26)    0.346         47 (27.8)    0.84 (0.52-1.35)                  0.475         
  AA                  7 (4.3)      11 (4.7)            1.01 (0.38-2.69)    0.982         9 (5.3)      1.17 (0.42-3.26)                  0.761         
  GA+AA               58 (36.0)    75 (31.9)           0.83 (0.55-1.27)    0.395         56 (33.1)    0.88 (0.56-1.39)                  0.581         
  *MMP14* rs743257    CC           40 (26.0) \[7\]     59 (25.1) \[1\]     Ref.                       41 (24.4) \[1\]                   Ref.          
  CT                  73 (47.4)    104 (44.3)          0.97 (0.59-1.59)    0.892         76 (45.2)    1.02 (0.59-1.75)                  0.955         
  TT                  41 (26.6)    72 (30.6)           1.19 (0.68-2.07)    0.538         51 (30.4)    1.21 (0.67-2.21)                  0.526         
  CT+TT               114 (74.0)   176 (74.9)          1.05 (0.66-1.67)    0.848         127 (75.6)   1.09 (0.66-1.80)                  0.746         

Numbers in square brackets denote the number of patients with missing data. Significant values are printed in bold. CI = confidence interval; OR = odds ratio; SNP = single nucleotide polymorphism

In haplotype analysis, no significant associations with MM risk were observed, even when asbestos exposure was taken into account ([Table 4](#j_raon-2018-0005_tab_004){ref-type="table"}). Nevertheless, haplotypes that included the polymorphic *MMP2* rs243865 allele had slightly lower risk, consistent with single SNP analysis, but the association did not reach statistical significance.

###### 

The association of haplotypes with frequencies above 5% for investigated genes with risk for malignant mesotjelioma in patients with asbestos exposure

  Gene      Haplotype   Estimated frequency   OR (95% CI)          P
  --------- ----------- --------------------- -------------------- -------
  *MMP2*    CCA         0.377                 Ref.                 
            CCC         0.272                 1.14 (0.77 - 1.68)   0.518
            CTA         0.144                 1.14 (0.70 - 1.85)   0.599
            TCC         0.144                 0.77 (0.48 - 1.25)   0.291
            TCA         0.056                 0.59 (0.26 - 1.38)   0.223
  *MMP9*    ACGT        0.572                 Ref.                 
            GCGC        0.204                 0.86 (0.59 - 1.26)   0.440
            GCAC        0.137                 0.81 (0.52 - 1.26)   0.353
  *MMP14*   TGC         0.338                 Ref.                 
            TGT         0.267                 1.39 (0.94 - 2.06)   0.103
            CGT         0.125                 0.85 (0.52 - 1.37)   0.494
            TAT         0.110                 1.23 (0.71 - 2.12)   0.461
            CGC         0.080                 1.33 (0.71 - 2.46)   0.371

The single nucleotide polymorphisms are ordered from the 5'- to 3'-end as follows: *MMP2*:rs243865, rs243849, rs7201; *MMP9*:rs17576, rs17577, rs2250889, rs20544; *MMP14*:rs1042703, rs1042704, rs743257.

Discussion {#j_raon-2018-0005_s_004}
==========

This study investigated the influence of *MMP2*, *MMP9* and *MMP14* gene polymorphisms on baseline risk for MM in comparison with healthy control subjects. Carriers of *MMP2* rs243865 CT or CT/TT genotypes had significantly decreased risk for developing MM in comparison with CC homozygous genotype, especially in patients with known asbestos exposure.

*MMP2* rs243865 (c.-1306C\>T) is a promoter polymorphism and our prior *in silico* analysis has shown that it may influence binding of transcription factors and may alter chromatin states.[@j_raon-2018-0005_ref_007] The data on whether the *MMP2* rs243865 T allele has a protective function or if it contributes to higher risk for cancer, is somewhat conflicting for different malignancies.

*MMP* polymorphisms have been extensively studied in many different common and rarer malignancies.[@j_raon-2018-0005_ref_012],[@j_raon-2018-0005_ref_013] The most attractive and most significant *MMPs* in risk assessment studies were *MMP2*, *MMP9* and *MMP3* polymorphisms. *MMP2* rs243865, that was associated with modified cancer risk in our study, had the greatest influence on cancer risk in general. In accordance with our study, two meta-analysis presented the results showing that *MMP2* rs243865 polymorphism had a protective role in lung cancer susceptibility in both dominant and recessive models, which is consistent with our results. Seventeen studies were included in the meta-analysis and reported that the *MMP2* rs2438651 polymorphism had a protective role only in the Asian population.[@j_raon-2018-0005_ref_012],[@j_raon-2018-0005_ref_013]

Considering that lung cancer is the most common thoracic malignancy, these results can be parallel to a less common thoracic malignancy such as MM. However, *MMP* polymorphisms in other common malignancies in the Asian population have been frequently studied. A meta-analysis of 12 publications studying urinary (renal and bladder) cancers showed a lower risk for bladder cancer with the T allele of *MMP2* rs243865 in Asian patients but not in the Caucasian population.[@j_raon-2018-0005_ref_014]

All of the above discussed publications present the *MMP2* rs243865 T allele as having a somewhat protective role in cancer. There are publications that suggest the opposite effect of the T allele in *MMP2* rs243865. A control based study that included a Caucasian population investigated six different polymorphisms in *MMPs* and *TIMPs* in bladder cancer patients. They concluded that the combined genotype carrying *MMP2* rs243865 allele T with *MMP9* rs3918242 allele T was found to increase bladder cancer risk.[@j_raon-2018-0005_ref_015] These results are the opposite to the previously mentioned Asian based metaanalysis.[@j_raon-2018-0005_ref_014]

According to the db SNP and HapMap data on rs243865 frequency in genetically different populations, the C allele is more common in Caucasian populations. That can perhaps contribute to the different results in different studied populations.[@j_raon-2018-0005_ref_016]

Nevertheless, all of the cited studies find that *MMP2* rs243865 could play a role as a risk factor in a variety of different malignancies. With regard to the *MMP2* rs243865, T allele containing genotypes seem to have a protective role in predominantly thoracic malignancies, such as lung cancer and MM.

Genome Wide Associated Study (GWAS) of 759 subjects in the Northern Italian population investigated 15 different SNPs in several genes, and one of them was *MMP14* rs2236304. Almost all of these SNPs had either a significant positive (higher risk after asbestos exposure) or negative (lower risk after asbestos exposure) interaction with asbestos exposure, even after statistical corrections (Bonferroni) had been applied. But, the study has some limitations, such asthe small sample size, the age unbalanced control group and the possible rare genetics variants that could have been excluded from the GWAS statistical analysis.[@j_raon-2018-0005_ref_017]

The *MMP2* rs243865, T allele genotypes seem to have a protective role in predominantly thoracic malignancies, such as lung cancer and MM. Moreover, thoracic malignancies are also well known to have a strong environmental component (eg. smoking, asbestos exposure).[@j_raon-2018-0005_ref_018] The gene-environment interactions have been studied extensively in MM. The study that investigated the role of microsomal epoxide hydrolase (*mEH*), glutathione S-transferases (*GSTM1*, *GSTT1*), N-acetytransferase 2 (*NAT2*), and cytochrome P1A1 (*CYP1A1*) genotypes concluded that the presence of synergisms between genotypes, i.e., *mEH* and *NAT2*, *mEH* and *GSTM*, and *NAT2* and *GSTM1* combined with the interaction observed with exposure to asbestos, suggests the presence of gene-environment and gene--gene interactions in the development of MM.[@j_raon-2018-0005_ref_019]

Our results suggest a combined effect of asbestos exposure and *MMP2* rs243865. Gene-environment interactions in asbestos related diseases have been previously studied in enzymes such as catalase (CAT), superoxide dismutase (SOD 2, SOD3) and inducible nitric oxide synthase (iNOS), which are part of the enzymatic defence system against reactive oxygen species (ROS). Besides gene-gene interactions between *MnSOD* Ala -9Val and *CAT*-262 C\>T polymorphisms as well as *iNOS* and *CAT* -262 C\>T polymorphisms and the risk of asbestosis, gene-environment interactions were also reported. A strong interaction was reported between *GSTM1* - null polymorphism and smoking, *iNOS* (CCTTT)n polymorphism and smoking, and between *iNOS* (CCTTT)n polymorphism and cumulative asbestos exposure, suggesting that interactions between different genotypes, genotypes and smoking, and between genotypes and asbestos exposure have an important influence on the development of asbestosis.[@j_raon-2018-0005_ref_020] These studies on asbestosis suggest, that gene-environment interactions should be investigated also in other asbestos related diseases, including MM, since asbestos exposure is a proven environmental risk factor in MM.

Despite some limitations of our study, such as a small sample size and a control group that was not appropriately age balanced, low rate of patient asbestos exposure and lacking this data of the control group, our results reached statistical significance and showed that there could be a genetic predisposition of certain MMP SNPs for MM and that there is a potential gene-environment interaction between MMP SNPs and asbestos that is a major risk factor for MM.

In conclusion, our data suggests that *MMP2* rs243865 polymorphism may have a protective role in malignant pleural mesothelioma. This finding is even more pronounced in patients exposed to asbestos, implying a strong gene-environment interaction.
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